DRUG
Retatrutide
Administered SC
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Status
Completed
Phase
Phase 2
Enrollment
146
Locations
42
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
Interventions
Treatment arms and agents.
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
Jul 7, 2023
Study start
Jul 20, 2023
Primary completion
Oct 1, 2025
Study completion
Oct 21, 2025
Results posted
Not reported
Registry updated
Nov 25, 2025
Outcomes
What the study measures.
Primary outcomes
Change from Baseline in Glomerular Filtration Rate (mGFR)
Time frame · Baseline, Week 24
The GFR in milliliter/minute per1.73 square meter (mL/min/1.73 m²) using iohexol clearance (mGFR-measured glomerular filtration rate)
Secondary outcomes
Change from Baseline in Urine Albumin-to-Creatinine Ratio (UACR)
Time frame · Baseline, Week 24
Change from Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa)
Time frame · Baseline, Week 24
Change from Baseline in Filtration Fraction Estimated from Measured Glomerular Filtration Rate (mGFR)
Time frame · Baseline, Week 24
Change from Baseline in Renal Mean Arterial Flow as Assessed by Magnetic Resonance Imaging (MRI), Corrected by Hematocrit
Time frame · Baseline, Week 24
Change from Baseline in in Mean Arterial Flow (MAF)
Time frame · Baseline, Week 24
Change from Baseline in Renal Artery Resistive Index (RARI)
Time frame · Baseline, Week 24
Change from Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) and End-diastolic Velocity (ESV)
Time frame · Baseline, Week 24
Change from Baseline in Global Renal Perfusion (MRI)
Time frame · Baseline, Week 24
Change from Baseline in Total Renal Parenchyma Volume (MRI)
Time frame · Baseline, Week 24
Change from Baseline in Renal Cortex Volume (MRI)
Time frame · Baseline, Week 24
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²) * Have either * no T2D with an HbA1c \< 6.5% or * have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening. * Have been diagnosed with chronic kidney disease (CKD). Exclusion Criteria: * Have a self-reported change in body weight \>5 kilogram (kg) (11 pounds) within 90 days before screening. * Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin * Have a prior or planned surgical treatment for obesity * Have Type 1 Diabetes (T1D) * Have acute or chronic hepatitis * Have a history of malignant disease within 5 years before screening.
Study locations
42 registered sites.
Canada · Italy · Spain · United Kingdom · United States. Showing up to 24 locations stored in the fast local snapshot.
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, United States
Care Access - 801 South Power Road, Mesa
Mesa, Arizona, United States
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
Medical Advancement Centers of Arizona
Tempe, Arizona, United States
Hope Clinical Research, Inc.
Canoga Park, California, United States
Catalina Research Institute, LLC
Montclair, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Teradan Clinical Trials, LLC
Brandon, Florida, United States
Suncoast Clinical Research, Inc.
New Port Richey, Florida, United States
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, United States
Indiana University Health University Hospital
Indianapolis, Indiana, United States
Prime Health and Wellness/SKYCRNG
Fayette, Mississippi, United States
Palm Research Center Tenaya
Las Vegas, Nevada, United States
NYU Langone Hospital - Long Island
Mineola, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Victorium Clinical Research - Houston
Houston, Texas, United States
Endocrine Ips, Pllc
Houston, Texas, United States
Tranquility Research
Webster, Texas, United States
Centricity Research Brampton Endocrinology
Brampton, Ontario, Canada
Circulate Cardiac & Vascular Centre
Burlington, Ontario, Canada
North York Diagnostic and Cardiac Centre
North York, Ontario, Canada
Stouffville Medical Research Institute Inc.
Stouffville, Ontario, Canada
Dr. Anil K. Gupta Medicine Professional Corporation
Toronto, Ontario, Canada
Related trials
More studies on Retatrutide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.